Longevity-focused biotech investment fell by nearly $1 billion in 2023 compared to the previous year, according to a report by Longevity Marketcap. The analysis found total funding dropped to $3.5 billion, down from $4.5 billion in 2022, despite significant financing rounds led by Altos Labs.
Altos Labs secured the largest share of funding with a $1 billion round, highlighting continued investor interest in cellular reprogramming and aging research. The company focuses on developing therapies to restore cell health and reverse disease by targeting biological aging processes.
The report noted that other major raises included Retro Biosciences and NewLimit, which also attracted large investments into reprogramming technologies. Despite this, the broader decline suggests that investors have become more selective, favouring later‑stage or better‑capitalised companies rather than early‑stage startups.
Longevity Marketcap said that investment into companies directly targeting aging biology still makes up a small fraction of overall biotech funding. The company claims this signals a need for more clinical data and clearer regulatory pathways to maintain growth in the sector.
The report highlighted a shift in investor focus towards companies closer to clinical validation and revenue generation, with a reduced appetite for riskier, discovery‑stage ventures. Analysts believe that while large players like Altos Labs continue to attract capital, the overall funding landscape for longevity biotech remains challenging.
